Entering text into the input field will update the search result below

3 Things In Biotech You Should Learn Today: November 2, 2017

Nov. 02, 2017 8:00 AM ETAGIO, BLUE, JUNO, NVS1 Comment
Zach Hartman profile picture
Zach Hartman


  • Agios Pharmaceuticals looks toward first IDH1 approval in AML treatment.
  • Juno looks not to be forgotten in the CAR-T cell race.
  • bluebird also headlines in non-malignant heme disorders at ASH.

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Agios Pharmaceuticals looks toward first IDH1 approval in AML treatment

Company: Agios Pharmaceuticals (AGIO)

Therapy: Ivosidenib, an IDH1 inhibitor

Disease: Acute myeloid leukemia (AML)

News: AGIO will present new findings from a clinical trial investigating the IDH1 inhibitor ivosidenib in IDH-mutant AML at ASH 2017 in Atlanta in December. The most advanced of these clinical studies will be presented in abstract 639, which covers a phase 1b/2 study of IDH inhibitors (ivosidenib or the recently approved enasidenib) in combination with azacitidine. AGIO reports favorable rates of blast cell control in a patient population whose average age is 81 years old.

Looking forward: These early stage studies might give you pause, but it's important to remember that enasidenib came out of nowhere and got approval based on promising early-stage clinical data. Two other abstracts highlight the favorable tolerability of ivosidenib monotherapy and in combination with induction chemotherapy for AML. So it looks like there is a strong chance for AGIO to build a small empire of IDH inhibitors on the backs of enasidenib and ivosidenib.

Juno looks not to be forgotten in the CAR-T cell race

Company: Juno Therapeutics (JUNO)

Therapy: JCAR017, a CD19-directed CAR-T cell therapy

Disease: Diffuse large B-cell lymphoma (DLBCL)

News: JUNO announced that it would also highlight new efficacy data at ASH 2017. The TRANSCEND study is featured most heavily, with primary data presented in abstract 581. In the 68 evaluable patients, 75% achieved a response and 56% of the patients achieved a complete response as their best overall response. In patients strictly meeting the inclusion criteria for TRANSCEND, the median overall survival had not been reached at the time

This article was written by

Zach Hartman profile picture
I am a former PhD scientist-turned-writer focused on cancer education. My writings in Seeking Alpha have been devoted to helping people identify promising investment opportunities in cancer research through commentary of recent events. Readers can learn more about other aspects of cancer research by visiting my site Invest Against Cancer.I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.